Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Zakharia Y, McWilliams RR, Rixe O, Drabick J, Shaheen MF, Grossmann KF, Kolhe R, Pacholczyk R, Sadek R, Tennant LL, Smith CM, Kennedy EP, Link CJ Jr, Vahanian NN, Yu J, Shen SS, Brincks EL, Rossi GR, Munn D, Milhem M. Zakharia Y, et al. Among authors: vahanian nn. J Immunother Cancer. 2021 Jun;9(6):e002057. doi: 10.1136/jitc-2020-002057. J Immunother Cancer. 2021. PMID: 34117113 Free PMC article. Clinical Trial.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ, Lin RS, Royer-Joo S, Liang X, Salphati L, Morrissey KM, Mahrus S, McCall B, Pirzkall A, Munn DH, Janik JE, Khleif SN. Nayak-Kapoor A, et al. Among authors: vahanian nn. J Immunother Cancer. 2018 Jun 20;6(1):61. doi: 10.1186/s40425-018-0351-9. J Immunother Cancer. 2018. PMID: 29921320 Free PMC article. Clinical Trial.
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.
Kumar S, Jaipuri FA, Waldo JP, Potturi H, Marcinowicz A, Adams J, Van Allen C, Zhuang H, Vahanian N, Link C Jr, Brincks EL, Mautino MR. Kumar S, et al. Eur J Med Chem. 2020 Jul 15;198:112373. doi: 10.1016/j.ejmech.2020.112373. Epub 2020 May 1. Eur J Med Chem. 2020. PMID: 32422549 Free article.
Herpes simplex amplicon vectors.
Link CJ, Vahanian NN, Wang S. Link CJ, et al. Among authors: vahanian nn. Methods Mol Med. 2003;76:61-87. doi: 10.1385/1-59259-304-6:61. Methods Mol Med. 2003. PMID: 12526159 No abstract available.
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Coveler AL, et al. Among authors: vahanian nn. Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26787078 Review.
A phase I study of indoximod in patients with advanced malignancies.
Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. Soliman HH, et al. Among authors: vahanian nn. Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. Oncotarget. 2016. PMID: 27008709 Free PMC article. Clinical Trial.
28 results